Compare CRNC & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNC | VALN |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.9M | 495.5M |
| IPO Year | 2019 | 2021 |
| Metric | CRNC | VALN |
|---|---|---|
| Price | $8.45 | $6.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $10.25 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 700.2K | 78.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,781,000.00 | N/A |
| Revenue This Year | $27.18 | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.85 | $4.75 |
| 52 Week High | $13.74 | $12.23 |
| Indicator | CRNC | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 66.26 |
| Support Level | $7.72 | $5.03 |
| Resistance Level | $9.39 | $7.31 |
| Average True Range (ATR) | 0.40 | 0.23 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 67.53 | 59.80 |
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.